


## Antifungal agents



- A history of pharmaceutical neglect:
  - Rare
  - Difficult to devise
  - Difficult to test in vitro
  - Not remunerative
- Escalating pace of research but
- Old gold standard

## Polyene structure

Lipophilic, hydrophobic, hydrophilic, amphipathic, amphoteric



amphotericin B

## Available classes

- **Polyenes** (cell membrane synthesis)
- **Azoles** (cell membrane synthesis)
- **Echinocandins** (cell wall synthesis)
- Miscellaneous (nucleic acid, cell membrane synthesis)


## Polyene mechanism of action

- Macrolide ring inserts into membrane parallel to phospholipid chains, binding to sterols
- Cylindrical channels form
- Cations, then macromolecules leak out
- Cell dies

## 1. Polyenes

- First antifungal antibiotics
- Isolated from *Streptomyces* spp.
- General structure:
  - Polyenes (multiple conjugated double bonds)
  - Macrolides (large rings with lactone linkage)

## Polyene action



## Polyene resistance

- Most clinically important fungi sensitive
- Dermatophytes resistant
- Inducible resistance rare (old drugs still work)
- Inherent resistance due to diminished membrane ergosterol with less affinity for drug

## Amphotericin B

- Colloidal dispersion in deoxycholate (bile salt)
- Protein bound. Urine and CSF concentrations low. Tissue stores slowly released
- Significant toxicity:
  - Infusion-related
  - Cumulative

## Polyenes: Nystatin

- 1950 in NYState
- Topical administration only
- Too toxic for systemic administration
- Uses:
  - Skin and mucosal candida infection especially oral thrush. No effect on dermatophytes

## Infusion-related AmB toxicity

- Dramatic infusion-related **fever, chills, nausea, vomiting, diarrhea, dyspnea**
- ?cytokine/prostaglandin related
- Treatment: symptomatic premedication
  - Acetaminophen
  - Benadryl
  - Cortisone
  - Demerol
  - ?Duration of infusion

## Amphotericin B

- 1954 from Venezuela
- Not soluble in water at physiologic pH
- Not orally absorbed
- Occasional oral use of suspension for "topical" treatment of oral or esophageal candidiasis
- IV use: gold standard of antifungals

## Cumulative AmB toxicity


- **Renal:** characteristic cation-wasting nephropathy days-weeks into treatment. Low K<sup>+</sup>, Mg<sup>++</sup>, elevated creatinine. Treatment-limiting. (vasoconstriction, tubular cell lysis)
- **Hematologic:** characteristic normocytic anemia (direct marrow toxicity /renal)

## Amphotericin B uses

- Systemic fungal diseases caused by
  - **Yeasts** (candidiasis, cryptococcosis)
  - **Molds** (aspergillosis, mucormycosis)
  - **Dimorphs** (histo, blasto, cocci)
- Toxicity has shaped usage patterns

## Azole structures

- Fluconazole: bis-triazole
- Ketoconazole: imidazole



## Amphotericin B modifications

- Drug encased in liposomes or otherwise highly lipid associated has less toxicity and equivalent efficacy
- Mechanism unclear (?direct delivery by macrophages)
- **Liposomal**
- **Lipid complex**
- **Colloidal dispersion**
- Used in confirmed disease
- \$\$\$

## Azole mechanism of action (and toxicity)

- Inhibit fungal cytochrome P450 enzymes which demethylate lanosterol to ergosterol
  - Block formation of ergosterol
  - Cause accumulation of toxic alpha-14 methyl esters in fungal cell
  - Sabotage membrane integrity
- “Fungistatic”

## 2. Azoles

- 1970s to present
- From topical to powerful oral and IV drugs
- Imidazoles: 2N in 5-membered ring
- Triazoles: 3N in 5-membered ring

## Toxicity of Azoles

- inhibit cholesterol-dependent steroid hormone synthesis (testosterone; cortisol)
- Lead to accumulation of metabolites with aldosterone-like effects
- Interfere with metabolism of other cytochrome P450 metabolized drugs

## Resistance to Azoles

- Intrinsic, esp. nonalbicans Candida
- Inducible rare, but increasing with increasing use
  - Alteration in P450 enzymes
  - Membrane lipid changes with decreased permeability

## Newer azoles: Fluconazole

- 1990
  - Soluble in water at neutral pH.
  - Good oral absorption, urine and CSF penetration
  - IV form available
  - Toxicity primarily hepatic
- Clinical uses:**
- Cryptococcal meningitis
  - Mucosal and esophageal candidiasis
  - Systemic candidiasis (efficacy rivals AmB in some settings)
  - Cocci

## Older Azoles

- **Clotrimazole** (Mycelex, Desenex, Lotrimin, Gyne-lotrimin)
- **Miconazole** (Monistat)
- **Terconazole** (Terazol)
- Topical only
- Minimal toxicity
- Used for dermatophyte and mucosal candidal infections

## Newer azoles: Itraconazole

- 1992
  - Poorly water-soluble
  - Protein and tissue-bound.
  - Very high adipose and keratinized tissue levels
- Clinical uses:**
- Sporotrichosis
  - Histoplasmosis
  - Blastomycosis
  - Cocci
  - Nail dermatophytes
  - Some activity against aspergillosis, sometimes.

## Newer azoles: Ketoconazole

- 1983
  - Soluble in water at acid pH
  - Highly protein/tissue bound
  - Dose-related adrenal and testosterone suppression
- Clinical uses:**
- Mucosal candidiasis (largely supplanted)
  - Sporotrichosis
  - Cocci
  - Pityriasis and dermatophytes (Nizoral shampoo)

## Newest azole: Voriconazole

- Synthetic derivative of fluconazole with oral and IV dosing
  - Unique visual toxicity
- Clinical uses:**
- Enhanced in vitro activity against Aspergillus, resistant Candida
  - Promising in vivo results

### 3. Echinocandins

- Inhibit fungal cell wall synthesis
- Irreversible inhibitors of 1,3 beta glucan synthase
- "Fungicidal" against wide range
- Little direct human toxicity

### Other agents


#### Griseofulvin (1939)

- Disrupts microtubules
- Active only against **dermatophytes**, and not very.
- Relatively nontoxic
- Heading out

#### Allylamines and thiocarbamates

- Inhibit squalene epoxidase (ergosterol synthesis)
- **Dermatophytes** only
- Lamisil (terbinafine)

### Echinocandin action



### Fluorocytosine (5-FC, Flucytosine)

- Deaminated to 5-FU by bacterial and fungal cells
- Inhibits DNA synthesis in range of pathogens
- Rapid evolution of resistance precludes solo use
- Synergy in cryptococcosis, ?others
- Toxicity: **bone marrow suppression, gastritis**


### Echinocandins

#### Caspofungin: January 2001

- Slow IV infusion with infusion-related events, but generally well tolerated
- Approved for invasive aspergillosis failing other therapy

Others: **Micafungin** for esophageal candidiasis

### Clinical options: mucosal candidiasis



- Topical polyene
- Topical azole
- Oral azole
- IV azole
- IV Amphotericin B
- Echinocandin?
- Remove breach in defense!


### Clinical options: dermatophytes

- Topical azole
- Systemic azole (especially nails)
- Allylamine
- (griseofulvin)




### Clinical options: systemic candidiasis

- Amphotericin B
- Lipid-associated amphotericin B
- Fluconazole
- Voriconazole
- Caspofungin



### Clinical options: Histo, Blasto, Cocci

- Amphotericin B
- Lipid-associated amphotericin B
- Newer azoles, oral or IV



### Clinical options: aspergillosis

- Amphotericin B
- Lipid-associated amphotericin B
- Voriconazole
- Caspofungin



### Clinical options: cryptococcal meningitis

- Amphotericin B
- Fluconazole
- Itraconazole
- Synergy with 5-FC



### Mortality due to mycoses, 1980-97

